tetano
Editor, Senior Moderator
Vaccine
. 2021 Jul 31;S0264-410X(21)00926-9.
doi: 10.1016/j.vaccine.2021.07.048. Online ahead of print.
Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine
Esther Redondo[SUP] 1 [/SUP], Georgina Drago[SUP] 2 [/SUP], Juan Luis López-Belmonte[SUP] 3 [/SUP], Jose María Guillén[SUP] 4 [/SUP], Helene Bricout[SUP] 5 [/SUP], Fabián P Alvarez[SUP] 5 [/SUP], Daniel Callejo[SUP] 6 [/SUP], Ángel Gil de Miguel[SUP] 7 [/SUP]
Affiliations
Abstract
Background: The normal ageing process is accompanied by immunosenescence and a progressive weakening of the immune system. High-dose inactivated influenza quadrivalent vaccine (HD-QIV) has shown greater immunogenicity, relative efficacy, and effectiveness than the standard-dose inactivated quadrivalent vaccine (SD-QIV). The aim of the study was to assess the cost-utility of an HD-QIV strategy compared with an adjuvanted trivalent inactivated vaccine (aTIV) strategy in the population above 65 years of age in Spain.
Methods: We evaluated the public health and economic benefits of alternatives by using a decision-tree model, which included influenza cases, visits to the general practitioner (GP), visits to the emergency department (ED), hospitalisations, and mortality related to influenza. We performed deterministic and probabilistic sensitivity analyses to account for both epidemiological and economical sources of uncertainty.
Results: Our results show that switching from aTIV strategy to HD-QIV would prevent 36,476 cases of influenza, 5,143 visits to GP, 1,054 visits to the ED, 9,193 episodes of hospitalisation due to influenza or pneumonia, and 357 deaths due to influenza - increasing 3,514 life-years and 3,167 quality-adjusted life-years (QALYs). Healthcare costs increase by €78,874,301, leading to an incremental cost-effectiveness ratio (ICER) of €24,353/QALY. The sensitivity analysis indicates that the results are rather robust.
Conclusion: Our analysis shows that HD-QIV in people over 65 years of age is an influenza-prevention strategy that is at least cost-effective, if not dominant, in Spain. It reduces cases of influenza, GP visits, hospitalisations, deaths, and associated healthcare costs.
Keywords: Aged; Cost-effectiveness; HD-QIV; Health services for the aged; Influenza.
. 2021 Jul 31;S0264-410X(21)00926-9.
doi: 10.1016/j.vaccine.2021.07.048. Online ahead of print.
Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine
Esther Redondo[SUP] 1 [/SUP], Georgina Drago[SUP] 2 [/SUP], Juan Luis López-Belmonte[SUP] 3 [/SUP], Jose María Guillén[SUP] 4 [/SUP], Helene Bricout[SUP] 5 [/SUP], Fabián P Alvarez[SUP] 5 [/SUP], Daniel Callejo[SUP] 6 [/SUP], Ángel Gil de Miguel[SUP] 7 [/SUP]
Affiliations
- PMID: 34344553
- DOI: 10.1016/j.vaccine.2021.07.048
Abstract
Background: The normal ageing process is accompanied by immunosenescence and a progressive weakening of the immune system. High-dose inactivated influenza quadrivalent vaccine (HD-QIV) has shown greater immunogenicity, relative efficacy, and effectiveness than the standard-dose inactivated quadrivalent vaccine (SD-QIV). The aim of the study was to assess the cost-utility of an HD-QIV strategy compared with an adjuvanted trivalent inactivated vaccine (aTIV) strategy in the population above 65 years of age in Spain.
Methods: We evaluated the public health and economic benefits of alternatives by using a decision-tree model, which included influenza cases, visits to the general practitioner (GP), visits to the emergency department (ED), hospitalisations, and mortality related to influenza. We performed deterministic and probabilistic sensitivity analyses to account for both epidemiological and economical sources of uncertainty.
Results: Our results show that switching from aTIV strategy to HD-QIV would prevent 36,476 cases of influenza, 5,143 visits to GP, 1,054 visits to the ED, 9,193 episodes of hospitalisation due to influenza or pneumonia, and 357 deaths due to influenza - increasing 3,514 life-years and 3,167 quality-adjusted life-years (QALYs). Healthcare costs increase by €78,874,301, leading to an incremental cost-effectiveness ratio (ICER) of €24,353/QALY. The sensitivity analysis indicates that the results are rather robust.
Conclusion: Our analysis shows that HD-QIV in people over 65 years of age is an influenza-prevention strategy that is at least cost-effective, if not dominant, in Spain. It reduces cases of influenza, GP visits, hospitalisations, deaths, and associated healthcare costs.
Keywords: Aged; Cost-effectiveness; HD-QIV; Health services for the aged; Influenza.